Mass spectrometry for translational proteomics: progress and clinical implications

Genome Medicine

Volumn 4, Issue 8, 2012, Pages

  Baker, Erin S ^a   Liu, Tao ^a   Petyuk, Vladislav A ^a   Burnum Johnson, Kristin E ^a   Ibrahim, Yehia M ^a   Anderson, Gordon A ^a   Smith, Richard D ^a  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

Biomarker; clinical proteomics; Ion mobility separations; Mass spectrometry; Multiple reaction monitoring; Selected reaction monitoring; Shotgun proteomics; Targeted proteomics; Translational proteomics

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C PEPTIDE; CARCINOEMBRYONIC ANTIGEN; CERULOPLASMIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4; FERRITIN; HAPTOGLOBIN; IMMUNOGLOBULIN M; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPROTEIN A; MYELIN BASIC PROTEIN; MYOGLOBIN; OROSOMUCOID; PREALBUMIN; PROSTATE SPECIFIC ANTIGEN; THROMBOPLASTIN; THYROGLOBULIN; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR BINDING PROTEIN; UNINDEXED DRUG;

ANTIBODY AFFINITY; BLOOD SAMPLING; DISSOCIATION; HISTOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ION MOBILITY SPECTROMETRY; IONIZATION; LASER CAPTURE MICRODISSECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; RISK FACTOR;

EID: 84865235673     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm364     Document Type: Review

References (78)

1. Bendall SC, Simonds EF, Qiu P, Amir E-AD, Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI, Balderas RS, Plevritis SK, Sachs K, Pe'er D, Tanner SD, Nolan GP. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011, 332:687-696. 10.1126/science.1198704, 3273988, 21551058.
2. Addona TA, Shi X, Keshishian H, Mani DR, Burgess M, Gillette MA, Clauser KR, Shen D, Lewis GD, Farrell LA, Fifer MA, Sabatine MS, Gerszten RE, Carr SA. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol 2011, 29:635-643. 10.1038/nbt.1899, 3366591, 21685905.
3. Whiteaker JR, Lin C, Kennedy J, Hou L, Trute M, Sokal I, Yan P, Schoenherr RM, Zhao L, Voytovich UJ, Kelly-Spratt KS, Krasnoselsky A, Gafken PR, Hogan JM, Jones LA, Wang P, Amon L, Chodosh LA, Nelson PS, McIntosh MW, Kemp CJ, Paulovich AG. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol 2011, 29:625-634. 10.1038/nbt.1900, 3232032, 21685906.
4. Saffert RT, Cunningham SA, Ihde SM, Jobe KE, Mandrekar J, Patel R. Comparison of Bruker Biotyper matrix-assisted laser desorption ionization-time of flight mass spectrometer to BD Phoenix automated microbiology system for identification of gram-negative bacilli. J Clin Microbiol 2011, 49:887-892. 10.1128/JCM.01890-10, 3067728, 21209160.
5. Bizzini A, Durussel C, Bille J, Greub G, Prod'hom G. Performance of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of bacterial strains routinely isolated in a clinical microbiology laboratory. J Clin Microbiol 2010, 48:1549-1554. 10.1128/JCM.01794-09, 2863943, 20220166.
6. American Medical Association. Proteomics. , http://www.ama-assn.org/ama/pub/physician-resources/medical-science/gene tics-molecular-medicine/current-topics/proteomics.page
7. Pruitt K, Brown G, Tatusova T, Maglott D. The Reference Sequence (RefSeq) Database. The NCBI Handbook [Internet]. 9 October 2002 (updated 6 April 2012)., http://www.ncbi.nlm.nih.gov/books/NBK21091
8. Pruitt KD, Tatusova T, Maglott DR. NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 2005, 33:D501-504. 10.1093/nar/gki476, 539979, 15608248.
9. Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet 2011, 12:217-44. 10.1146/annurev-genom-082410-101446, 21721939.
10. Hutchinson L. Personalized cancer medicine: era of promise and progress. Nat Rev Clin Oncol 2011, 8:121. 10.1038/nrclinonc.2011.14, 21364683.
11. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867. 10.1074/mcp.R200007-MCP200, 12488461.
12. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998, 279:1542-1547. 10.1001/jama.279.19.1542, 9605898.
13. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996, 335:1342-1349. 10.1056/NEJM199610313351802, 8857017.
14. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397. 10.1056/NEJMoa032804, 15070788.
15. Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983. 10.1038/nbt1235, 16900146.
16. Anderson NL. The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cell Proteomics 2005, 4:1441-1444. 10.1074/mcp.I500001-MCP200, 16020426.
17. Jacobs JM, Adkins JN, Qian WJ, Liu T, Shen Y, Camp DG, Smith RD. Utilizing human blood plasma for proteomic biomarker discovery. J Proteome Res 2005, 4:1073-1085. 10.1021/pr0500657, 16083256.
18. Ricós C, Iglesias N, García-Lario JV, Simón M, Cava F, Hernández A, Perich C, Minchinela J, Alvarez V, Doménech MV, Jiménez CV, Biosca C, Tena R. Within-subject biological variation in disease: collated data and clinical consequences. Ann Clin Biochem 2007, 44:343-352. 10.1258/000456307780945633, 17594781.
19. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Population proteomics: the concept, attributes, and potential for cancer biomarker research. Mol Cell Proteomics 2006, 5:1811-1818. 10.1074/mcp.R600006-MCP200, 16735302.
20. Mirsky P, Chatterjee A, Sauer-Budge AF, Sharon A. An automated, parallel processing approach to biomolecular sample preparation. J Lab Autom 2012, 17:116-124.
21. Unwin RD, Griffiths JR, Whetton AD. Simultaneous analysis of relative protein expression levels across multiple samples using iTRAQ isobaric tags with 2D nano LC-MS/MS. Nat Protoc 2010, 5:1574-1582. 10.1038/nprot.2010.123, 21085123.
22. Gilar M, Greibrokk T. 2D LC - embraced by life-science research and drug development. J Sep Sci 2012, 35. NA.
23. Belov ME, Prasad S, Prior DC, Danielson WF, Weitz K, Ibrahim YM, Smith RD. Pulsed multiple reaction monitoring approach to enhancing sensitivity of a tandem quadrupole mass spectrometer. Anal Chem 2011, 83:2162-2171. 10.1021/ac103006b, 3059105, 21344863.
24. Ibrahim Y, Belov ME, Tolmachev AV, Prior DC, Smith RD. Ion funnel trap interface for orthogonal time-of-flight mass spectrometry. Anal Chem 2007, 79:7845-7852. 10.1021/ac071091m, 2516353, 17850113.
25. Gillet LC, Navarro P, Tate S, Röst H, Selevsek N, Reiter L, Bonner R, Aebersold R. Targeted data extraction of the MS/MS spectra generated by data independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics 2012, 11:O111.016717. 10.1074/mcp.O111.016717, 22261725.
26. Panchaud A, Scherl A, Shaffer SA, von Haller PD, Kulasekara HD, Miller SI, Goodlett DR. Precursor acquisition independent from ion count: how to dive deeper into the proteomics ocean. Anal Chem 2009, 81:6481-6488. 10.1021/ac900888s, 3086478, 19572557.
27. Röst H, Malmström L, Aebersold R. A computational tool to detect and avoid redundancy in selected reaction monitoring. Mol Cell Proteomics 2012, 11:540-549. 10.1074/mcp.M111.013045, 22535207.
28. Schilling B, Rardin MJ, MacLean BX, Zawadzka AM, Frewen BE, Cusack MP, Sorensen DJ, Bereman MS, Jing E, Wu CC, Verdin E, Kahn CR, Maccoss MJ, Gibson BW. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol Cell Proteomics 2012, 11:202-214. 10.1074/mcp.M112.017707, 3418851, 22454539.
29. Farrah T, Deutsch EW, Kreisberg R, Sun Z, Campbell DS, Mendoza L, Kusebauch U, Brusniak MY, Hüttenhain R, Schiess R, Selevsek N, Aebersold R, Moritz RL. PASSEL: The PeptideAtlas SRMexperiment library. Proteomics 2012, 12:1170-1175. 10.1002/pmic.201100515, 22318887.
30. McAlister GC, Coon JJ. Decision tree-driven tandem mass spectrometry for shotgun proteomics. Nat Methods 2008, 5:959-964. 10.1038/nmeth.1260, 2597439, 18931669.
31. Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001, 19:242-247. 10.1038/85686, 11231557.
32. Schuchard M, Melm C, Crawford H, Chapman S, Cockrill S, Ray K, Mehigh R, Chen D, Scott G. Specific depletion of twenty high abundance proteins from human plasma. Poster presented at NCI Proteomic Technologies Reagents Resource Workshop, 12-13 December 2005 , http://www.scribd.com/doc/12287730/Specific-Depletion-of-Twenty-High-Abu ndance-Proteins
33. Shi T, Zhou JY, Gritsenko MA, Hossain M, Camp DG, Smith RD, Qian WJ. IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery. Methods 2012, 56:246-253. 10.1016/j.ymeth.2011.09.001, 21925605.
34. Qian WJ, Kaleta DT, Petritis BO, Jiang H, Liu T, Zhang X, Mottaz HM, Varnum SM, Camp DG, Huang L, Fang X, Zhang WW, Smith RD. Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteomics 2008, 7:1963-1973. 10.1074/mcp.M800008-MCP200, 2559934, 18632595.
35. Zhou JY, Petritis BO, Petritis K, Norbeck AD, Weitz KK, Moore RJ, Camp DG, Kulkarni RN, Smith RD, Qian WJ. Mouse-specific tandem IgY7-SuperMix immunoaffinity separations for improved LC-MS/MS coverage of the plasma proteome. J Proteome Res 2009, 8:5387-5395. 10.1021/pr900564f, 2783519, 19722698.
36. Faca V, Pitteri SJ, Newcomb L, Glukhova V, Phanstiel D, Krasnoselsky A, Zhang Q, Struthers J, Wang H, Eng J, Fitzgibbon M, McIntosh M, Hanash S. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 2007, 6:3558-3565. 10.1021/pr070233q, 17696519.
37. Shen Y, Zhao R, Berger SJ, Anderson GA, Rodriguez N, Smith RD. High-efficiency nanoscale liquid chromatography coupled on-line with mass spectrometry using nanoelectrospray ionization for proteomics. Anal Chem 2002, 74:4235-4249. 10.1021/ac0202280, 12199598.
38. Dowell JA, Frost DC, Zhang J, Li L. Comparison of two-dimensional fractionation techniques for shotgun proteomics. Anal Chem 2008, 80:6715-6723. 10.1021/ac8007994, 2548321, 18680313.
39. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20:3551-3567. 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2 -2, 10612281.
40. Yates JR, Eng JK, McCormack AL, Schieltz D. Method to correlate tandem mass spectra of modified peptides to amino acid sequences in the protein database. Anal Chem 1995, 67:1426-1436. 10.1021/ac00104a020, 7741214.
41. Beavis RC, Fenyo D. A method for assessing the statistical significance of mass spectrometry-based protein identifications using general scoring schemes. Anal Chem 2003, 75:768-774. 10.1021/ac0258709, 12622365.
42. Nesvizhskii AI. A survey of computational methods and error rate estimation procedures for peptide and protein identification in shotgun proteomics. J Proteomics 2010, 73:2092-2123. 10.1016/j.jprot.2010.08.009, 2956504, 20816881.
43. Gupta N, Bandeira N, Keich U, Pevzner PA. Target-decoy approach and false discovery rate: when things may go wrong. J Am Soc Mass Spectrom 2011, 22:1111-1120. 10.1007/s13361-011-0139-3, 3220955, 21953092.
44. Kim S, Gupta N, Pevzner PA. Spectral probabilities and generating functions of tandem mass spectra: a strike against decoy databases. J Proteome Res 2008, 7:3354-3363. 10.1021/pr8001244, 2689316, 18597511.
45. Xie F, Liu T, Qian WJ, Petyuk VA, Smith RD. Liquid chromatography-mass spectrometry-based quantitative proteomics. J Biol Chem 2011, 286:25443-25449. 10.1074/jbc.R110.199703, 3138289, 21632532.
46. Goshe MB, Smith RD. Stable isotope-coded proteomic mass spectrometry. Curr Opin Biotechnol 2003, 14:101-109. 10.1016/S0958-1669(02)00014-9, 12566009.
47. Geiger T, Cox J, Ostasiewicz P, Wisniewski JR, Mann M. Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat Methods 2010, 7:383-385. 10.1038/nmeth.1446, 20364148.
48. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 3:1154-1169. 10.1074/mcp.M400129-MCP200, 15385600.
49. Zieske LR. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J Exp Bot 2006, 57:1501-1508. 10.1093/jxb/erj168, 16574745.
50. Qian WJ, Liu T, Petyuk VA, Gritsenko MA, Petritis BO, Polpitiya AD, Kaushal A, Xiao W, Finnerty CC, Jeschke MG, Jaitly N, Monroe ME, Moore RJ, Moldawer LL, Davis RW, Tompkins RG, Herndon DN, Camp DG, Smith RD, . Inflammation and the Host Response to Injury Large Scale Collaborative Research Program Large-scale multiplexed quantitative discovery proteomics enabled by the use of an (18)O-labeled "universal" reference sample. J Proteome Res 2009, 8:290-299. 10.1021/pr800467r, 2752204, 19053531, Inflammation and the Host Response to Injury Large Scale Collaborative Research Program.
51. Nielsen ML, Vermeulen M, Bonaldi T, Cox J, Moroder L, Mann M. Iodoacetamide-induced artifact mimics ubiquitination in mass spectrometry. Nat Methods 2008, 5:459-460. 10.1038/nmeth0608-459, 18511913.
52. Zimmer JS, Monroe ME, Qian WJ, Smith RD. Advances in proteomics data analysis and display using an accurate mass and time tag approach. Mass Spectrom Rev 2006, 25:450-482. 10.1002/mas.20071, 1829209, 16429408.
53. Scicchitano MS, Dalmas DA, Boyce RW, Thomas HC, Frazier KS. Protein extraction of formalin-fixed, paraffin-embedded tissue enables robust proteomic profiles by mass spectrometry. J Histochem Cytochem 2009, 57:849-860. 10.1369/jhc.2009.953497, 2728129, 19471015.
54. Waldemarson S, Krogh M, Alaiya A, Kirik U, Schedvins K, Auer G, Hansson KM, Ossola R, Aebersold R, Lee H, Malmström J, James P. Protein expression changes in ovarian cancer during the transition from benign to malignant. J Proteome Res 2012, 11:2876-2889. 10.1021/pr201258q, 22471520.
55. Angel TE, Jacobs JM, Spudich SS, Gritsenko MA, Fuchs D, Liegler T, Zetterberg H, Camp DG, Price RW, Smith RD. The cerebrospinal fluid proteome in HIV infection: change associated with disease severity. Clin Proteomics 2012, 9:3. 10.1186/1559-0275-9-3, 3353874, 22433316.
56. Gallien S, Duriez E, Domon B. Selected reaction monitoring applied to proteomics. J Mass Spectrom 2011, 46:298-312. 10.1002/jms.1895, 21394846.
57. Stahl-Zeng J, Lange V, Ossola R, Eckhardt K, Krek W, Aebersold R, Domon B. . Mol Cell Proteomics 2007, 6:1809-1817. 10.1074/mcp.M700132-MCP200, 17644760.
58. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J Proteome Res 2004, 3:235-244. 10.1021/pr034086h, 15113099.
59. Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics 2010, 9:184-196. 10.1074/mcp.M900254-MCP200, 2808264, 19843560.
60. Hossain M, Kaleta DT, Robinson EW, Liu T, Zhao R, Page JS, Kelly RT, Moore RJ, Tang K, Camp DG, Qian WJ, Smith RD. Enhanced sensitivity for selected reaction monitoring mass spectrometry-based targeted proteomics using a dual stage electrodynamic ion funnel interface. Mol Cell Proteomics 2011, 10:M000062-MCP201. 3033664, 20410378.
61. Picotti P, Lam H, Campbell D, Deutsch EW, Mirzaei H, Ranish J, Domon B, Aebersold R. A database of mass spectrometric assays for the yeast proteome. Nat Methods 2008, 5:913-914. 10.1038/nmeth1108-913, 2770732, 18974732.
62. SRM Atlas. , http://www.srmatlas.org/
63. Lange V, Picotti P, Domon B, Aebersold R. Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 2008, 4:222. 2583086, 18854821.
64. Beavis RC, Craig R, Cortens JP. Open source system for analyzing, validating, and storing protein identification data. J Proteome Res 2004, 3:1234-1242. 10.1021/pr049882h, 15595733.
65. Fusaro VA, Mani DR, Mesirov JP, Carr SA. Prediction of high-responding peptides for targeted protein assays by mass spectrometry. Nat Biotechnol 2009, 27:190-198. 10.1038/nbt.1524, 2753399, 19169245.
66. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJ, Keshishian H, Hall SC, Allen S, Blackman RK, Borchers CH, Buck C, Cardasis HL, Cusack MP, Dodder NG, Gibson BW, Held JM, Hiltke T, Jackson A, Johansen EB, Kinsinger CR, Li J, Mesri M, Neubert TA, Niles RK, Pulsipher TC, Ransohoff D, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009, 27:633-641. 10.1038/nbt.1546, 2855883, 19561596.
67. Suhr H. Plasma Chromatography 1984, New York: Plenum Press.
68. Mason E, McDaniel E. Transport Properites of Ions in Gases 1988, New York: Wiley.
69. Guevremont R, Siu KW, Wang J, Ding L. Combined ion mobility/time-of-flight mass spectrometry study of electrospray-generated ions. Anal Chem 1997, 69:3959-3965. 10.1021/ac970359e, 21639212.
70. Baker ES, Tang K, Danielson WF, Prior DC, Smith RD. Simultaneous fragmentation of multiple ions using IMS drift time dependent collision energies. J Am Soc Mass Spectrom 2008, 19:411-419. 10.1016/j.jasms.2007.11.018, 2517259, 18226544.
71. Merenbloom SI, Koeniger SL, Valentine SJ, Plasencia MD, Clemmer DE. IMS-IMS and IMS-IMS-IMS/MS for separating peptide and protein fragment ions. Anal Chem 2006, 78:2802-2809. 10.1021/ac052208e, 16615796.
72. Pringle SD, Giles K, Wildgoose JL, Williams JP, Slade SE, Thalassinos K, Bateman RH, Bowers MT, Scrivens JH. An investigation of the mobility separation of some peptide and protein ions using a new hybrid quadrupole/travelling wave IMS/oa-ToF instrument. Int J Mass Spectrom 2007, 261:1-12.
73. Baker ES, Livesay EA, Orton DJ, Moore RJ, Danielson WF, Prior DC, Ibrahim YM, LaMarche BL, Mayampurath AM, Schepmoes AA, Hopkins DF, Tang K, Smith RD, Belov ME. An LC-IMS-MS platform providing increased dynamic range for high-throughput proteomic studies. J Proteome Res 2010, 9:997-1006. 10.1021/pr900888b, 2819092, 20000344.
74. Tang K, Shvartsburg AA, Lee HN, Prior DC, Buschbach MA, Li F, Tolmachev AV, Anderson GA, Smith RD. High-sensitivity ion mobility spectrometry/mass spectrometry using electrodynamic ion funnel interfaces. Anal Chem 2005, 77:3330-3339. 10.1021/ac048315a, 1829302, 15889926.
75. Shaffer SA, Tang K, Anderson GA, Prior DC, Udseth HR, Smith RD. A novel ion funnel for focusing ions at elevated pressure using electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 1997, 11:1813-1817.
76. Lindner M, Hoffmann GF, Matern D. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis 2010, 33:521-526. 10.1007/s10545-010-9076-8, 20373143.
77. Smith RD. Mass spectrometry in biomarker applications: from untargeted discovery to targeted verification, and implications for platform convergence and clinical application. Clin Chem 2012, 58:528-530. 10.1373/clinchem.2011.180596, 22194635.
78. Surinova S, Schiess R, Hüttenhain R, Cerciello F, Wollscheid B, Aebersold R. On the development of plasma protein biomarkers. J Proteome Res 2011, 10:5-16. 10.1021/pr1008515, 21142170.